Hypophosphatasia Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2026-2036

Market Overview:

The hypophosphatasia market reached a value of USD 772.9 Million across the top 7 markets (US, EU4, UK, and Japan) in 2025. Looking forward, IMARC Group expects the top 7 major markets to reach USD 1,100.4 Million by 2036, exhibiting a growth rate (CAGR) of 3.17% during 2026-2036.

The hypophosphatasia market has been comprehensively analyzed in IMARC's new report titled "Hypophosphatasia Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2026-2036". Hypophosphatasia (HPP) refers to a rare, inherited metabolic disorder characterized by decreased activity of the tissue-nonspecific alkaline phosphatase enzyme, resulting in impaired mineralization of bones and teeth. This condition affects people of all ages, but its severity varies widely, ranging from mild to life-threatening. The symptoms of the ailment primarily manifest in the skeletal system and can include weak and soft bones, fractures, stunted growth, and dental problems. Infants suffering from severe HPP may experience respiratory issues due to underdeveloped ribcages, while adults may suffer from recurrent fractures and early tooth loss. Numerous other features may include muscle weakness, joint pain, delayed motor development, etc. The diagnosis of the illness can be challenging due to its diverse clinical presentations and rarity. A thorough clinical evaluation, including a detailed medical history, physical examination, and assessment of biochemical markers, is recommended. Additionally, X-rays, genetic testing, and bone biopsies may aid in confirming the diagnosis among patients.

To get more information on this market, Request Sample

The escalating prevalence of somatic mutations in genetic materials, which can result in impaired bone mineralization and abnormal tooth development, is primarily driving the hypophosphatasia market. In addition to this, the inflating utilization of effective treatments, such as enzyme replacement therapy and bone-targeted therapies, like asfotase alfa, to manage and alleviate the symptoms of the disease is also creating a positive outlook for the market. These therapies help to improve bone mineralization and skeletal growth, enhancing the quality of life for individuals suffering from the ailment. Moreover, the growing adoption of physical and occupational therapies, since they work by strengthening muscles, promoting mobility, and encouraging gross motor skills to reduce some of the challenges associated with the disorder, is further bolstering the market growth. Apart from this, the increasing awareness of the condition, along with advancements in medical research activities to launch novel drugs and improve outcomes for patients, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of innovative treatments like gene therapy, which holds promise for correcting the genetic defects responsible for the disease, thereby potentially offering a curative approach and transforming the treatment landscape for HPP, is expected to drive the hypophosphatasia market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the hypophosphatasia market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for hypophosphatasia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the hypophosphatasia market in any manner.

Recent Developments:

• In October 2023, AM-Pharma B.V. reported positive clinical data from a Phase 1b study of its patented recombinant alkaline phosphatase, ilofotase alfa, as a potential enzyme replacement therapy for adult hypophosphatasia patients.

Key Highlights:

• In the United States, it affects roughly 500-600 people each year.
• In some inbred populations, such as Canadian Mennonites, the incidence is as high as one case every 2500 infants.
• The most severe forms of hypophosphatasia usually develop before birth or in early infancy.
• Infants with hypophosphatasia have a 50% mortality rate when symptoms appear within 6 months of birth.
• The most common cause of death in newborns with hypophosphatasia is respiratory problems.

Drugs:

STRENSIQ (asfotase alfa) is the first and only prescription medication used to treat persons with perinatal, infantile, and juvenile-onset hypophosphatasia. It is an innovative bone-targeted enzyme replacement therapy that addresses the root cause of hypophosphatasia by replacing the missing TNSALP enzyme.

Ilofotase alfa is a proprietary recombinant alkaline phosphatase derived from two human alkaline phosphatase isoforms that have been found to be stable and highly active in numerous clinical trials. In hypophosphatasia, ilofotase alfa targets high levels of pyridoxal-5′-phosphate and inorganic pyrophosphates, two disease-related biomarkers linked to bone mineralization and pain sensation.

ALXN-1850, also known as efzimfotase alfa, is a next-generation alkaline phosphatase that Alexion Pharmaceuticals is developing to treat hypophosphatasia. It is administered both intravenously and subcutaneously.

Time Period of the Study

• Base Year: 2025
• Historical Period: 2020-2025
• Market Forecast: 2026-2036

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the hypophosphatasia market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the hypophosphatasia market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current hypophosphatasia marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the hypophosphatasia market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2025 and how are they expected to perform till 2036?
• What was the country-wise size of the hypophosphatasia across the seven major markets in 2025 and what will it look like in 2036?
• What is the growth rate of the hypophosphatasia across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?

Epidemiology Insights

• What is the number of incident cases (2020-2036) of hypophosphatasia across the seven major markets?
• What is the number of incident cases (2020-2036) of hypophosphatasia by age across the seven major markets?
• What is the number of incident cases (2020-2036) of hypophosphatasia by gender across the seven major markets?
• How many patients are diagnosed (2020-2036) with hypophosphatasia across the seven major markets?
• What is the size of the hypophosphatasia patient pool (2020-2025) across the seven major markets?
• What would be the forecasted patient pool (2026-2036) across the seven major markets?
• What are the key factors driving the epidemiological trend hypophosphatasia of?
• What will be the growth rate of patients across the seven major markets?

Hypophosphatasia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for hypophosphatasia drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the hypophosphatasia market?
• What are the key regulatory events related to the hypophosphatasia market?
• What is the structure of clinical trial landscape by status related to the hypophosphatasia market?
• What is the structure of clinical trial landscape by phase related to the hypophosphatasia market?
• What is the structure of clinical trial landscape by route of administration related to the hypophosphatasia market?